NCT01631942View on ClinicalTrials.gov

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 26, 2012

Primary Completion Date

September 4, 2012

Study Completion Date

September 4, 2012

Conditions
Congenital Bleeding DisorderHaemophilia AHealthy
Interventions
DRUG

NNC172-2021

"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."

Trial Locations (6)

1090

Novo Nordisk Investigational Site, Vienna

10249

Novo Nordisk Investigational Site, Berlin

28046

Novo Nordisk Investigational Site, Madrid

34295

Novo Nordisk Investigational Site, Montpellier

69003

Novo Nordisk Investigational Site, Lyon

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY